Literature DB >> 27032890

Tetrahydroprotoberberine alkaloids with dopamine and σ receptor affinity.

Satishkumar Gadhiya1, Sudharshan Madapa2, Thomas Kurtzman3, Ian L Alberts4, Steven Ramsey5, Nagavara-Kishore Pillarsetty6, Teja Kalidindi6, Wayne W Harding7.   

Abstract

Two series of analogues of the tetrahydroprotoberberine (THPB) alkaloid (±)-stepholidine that (a) contain various alkoxy substituents at the C10 position and, (b) were de-rigidified with respect to (±)-stepholidine, were synthesized and evaluated for affinity at dopamine and σ receptors in order to evaluate effects on D3 and σ2 receptor affinity and selectivity. Small n-alkoxy groups are best tolerated by D3 and σ2 receptors. Among all compounds tested, C10 methoxy and ethoxy analogues (10 and 11 respectively) displayed the highest affinity for σ2 receptors as well as σ2 versus σ1 selectivity and also showed the highest D3 receptor affinity. De-rigidification of stepholidine resulted in decreased affinity at all receptors evaluated; thus the tetracyclic THPB framework is advantageous for affinity at dopamine and σ receptors. Docking of the C10 analogues at the D3 receptor, suggest that an ionic interaction between the protonated nitrogen atom and Asp110, a H-bond interaction between the C2 phenol and Ser192, a H-bond interaction between the C10 phenol and Cys181 as well as hydrophobic interactions of the aryl rings to Phe106 and Phe345, are critical for high affinity of the compounds.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  D3; Dopamine; Sigma; Stepholidine; THPB; Tetrahydroprotoberberine

Mesh:

Substances:

Year:  2016        PMID: 27032890      PMCID: PMC4833520          DOI: 10.1016/j.bmc.2016.03.037

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  42 in total

Review 1.  Sigma-1 receptors: potential targets for the treatment of substance abuse.

Authors:  Matthew J Robson; Bahar Noorbakhsh; Michael J Seminerio; Rae R Matsumoto
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  Sigma receptors: biology and function.

Authors:  J M Walker; W D Bowen; F O Walker; R R Matsumoto; B De Costa; K C Rice
Journal:  Pharmacol Rev       Date:  1990-12       Impact factor: 25.468

3.  Molecular insights into the D1R agonist and D2R/D3R antagonist effects of the natural product (-)-stepholidine: molecular modeling and dynamics simulations.

Authors:  Bian Li; Wei Li; Peng Du; Kun Qian Yu; Wei Fu
Journal:  J Phys Chem B       Date:  2012-07-03       Impact factor: 2.991

4.  Sigma 2 receptors as potential biomarkers of proliferation in breast cancer.

Authors:  R H Mach; C R Smith; I al-Nabulsi; B R Whirrett; S R Childers; K T Wheeler
Journal:  Cancer Res       Date:  1997-01-01       Impact factor: 12.701

5.  Haloperidol-sensitive (+)[3H]SKF-10,047 binding sites (sigma sites) exhibit a unique distribution in rat brain subcellular fractions.

Authors:  D J McCann; T P Su
Journal:  Eur J Pharmacol       Date:  1990-04-25       Impact factor: 4.432

6.  Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.

Authors:  Haifeng Sun; Liyuan Zhu; Huicui Yang; Wangke Qian; Lin Guo; Shengbin Zhou; Bo Gao; Zeng Li; Yu Zhou; Hualiang Jiang; Kaixian Chen; Xuechu Zhen; Hong Liu
Journal:  Bioorg Med Chem       Date:  2012-12-21       Impact factor: 3.641

Review 7.  Potential applications for sigma receptor ligands in cancer diagnosis and therapy.

Authors:  Aren van Waarde; Anna A Rybczynska; Nisha K Ramakrishnan; Kiichi Ishiwata; Philip H Elsinga; Rudi A J O Dierckx
Journal:  Biochim Biophys Acta       Date:  2014-08-27

Review 8.  The σ2 receptor: a novel protein for the imaging and treatment of cancer.

Authors:  Robert H Mach; Chenbo Zeng; William G Hawkins
Journal:  J Med Chem       Date:  2013-06-18       Impact factor: 7.446

Review 9.  Dopamine D3 receptor ligands with antagonist properties.

Authors:  Anneke E Hackling; Holger Stark
Journal:  Chembiochem       Date:  2002-10-04       Impact factor: 3.164

10.  The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer.

Authors:  Mehran Makvandi; Estifanos D Tilahun; Brian P Lieberman; Redmond-Craig Anderson; Chenbo Zeng; Kuiying Xu; Catherine Hou; Elizabeth S McDonald; Daniel A Pryma; Robert H Mach
Journal:  Biochem Biophys Res Commun       Date:  2015-10-09       Impact factor: 3.575

View more
  2 in total

1.  Synthesis and evaluation of C9 alkoxy analogues of (-)-stepholidine as dopamine receptor ligands.

Authors:  Sudharshan Madapa; Satishkumar Gadhiya; Thomas Kurtzman; Ian L Alberts; Steven Ramsey; Maarten Reith; Wayne W Harding
Journal:  Eur J Med Chem       Date:  2016-09-14       Impact factor: 6.514

Review 2.  Deep Learning in Drug Discovery and Medicine; Scratching the Surface.

Authors:  Dibyendu Dana; Satishkumar V Gadhiya; Luce G St Surin; David Li; Farha Naaz; Quaisar Ali; Latha Paka; Michael A Yamin; Mahesh Narayan; Itzhak D Goldberg; Prakash Narayan
Journal:  Molecules       Date:  2018-09-18       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.